Wise Chemical Company was sold by 2.38 billion
On the evening of June 12, Quantum Hi-Tech, which suspended trading for nearly half a year, issued a major asset restructuring plan. The company plans to issue shares and pay cash in combination with a total price of 2.38 billion yuan to purchase 100% equity of Shanghai Ruizhi Chemical Research Co., Ltd. ("Smart Chemical"). Among them, the portion of assets purchased for the issuance of shares was 1.632 billion yuan, and the portion of cash paid was 748 million yuan.
At the same time, Quantum Hi-Tech plans to raise 665 million yuan in matching funds, mainly for paying cash considerations and intermediary fees for this transaction. After the transaction was completed, Zeng Xianjing and Huang Yanling held a shareholding share of 20.91% of the listed company and remained the actual controller of the listed company.
In terms of performance commitment, Ruizhi Chemical promised that the net profit realized in 2017, 2018 and 2019 should be no less than 135 million yuan, 165 million yuan and 200 million yuan.
According to the announcement, Ruizhi Chemical was established in the Shanghai Free Trade Zone, one of the core assets of Shanghua Pharmaceutical Group (listed on the NYSE in 2010 and privatized in 2013). Huixin and his family were in 2003. Founded, the company is mainly engaged in CRO and CMO business related to new drug R&D outsourcing. Specifically, the CRO business is mainly for the research and development of new drugs for chemical drugs and biopharmaceuticals; the CMO business is mainly for the production process of chemical drugs and biopharmaceuticals, and small batch trials.
Ruizhi Chemical's pharmaceutical R&D platform has built a relatively complete and mature new drug pre-clinical R&D outsourcing industry chain. It is a leading CRO enterprise in China, serving nearly 1,000 large and medium-sized pharmaceutical companies and scientific research institutions, covering chemical drugs, biopharmaceuticals, etc. Different types of drugs, including chemical drugs, biopharmaceutical discovery, screening, analysis and other processes, can provide customers with pre-clinical integration services for drug development and biopharmaceutical drug development, and improve the efficiency of new drug research and development.
The CRO and CMO industries have developed rapidly in recent years, and the market demand has broad prospects. In terms of long-term trends, driven by the rise in industrial policies and new drug research and development costs, pharmaceutical R&D and production outsourcing aimed at improving efficiency and reducing costs have good prospects for development; from the short-term trend, they are consistent with “patent cliffs†and “drugsâ€. The impact of the “sexual evaluationâ€, pharmaceutical companies in the field of new drug research and development is expected to increase, and thus promote the growth of industry demand. In recent years, the domestic CRO and CMO industries have developed rapidly, and CRO companies such as WuXi PharmaTech, Kanglong Huacheng, Ruizhi Chemical, Taige Medicine, Boji Medicine, and CMO companies such as Hequan Pharmaceutical, Boteng and Kailaiying have emerged.
For Quantum Hi-Tech, which has been focusing on the big health industry, if the transaction is completed, it will also mark a major breakthrough in the company's industrial transformation and upgrading. It is reported that Quantum Hi-Tech has long been committed to the research, development, production and sales of the prebiotics series products represented by oligofructose and oligogalactose, and strives to create a leading brand in the micro-ecological health field. It will extend from the development, production and sales of a relatively simple prebiotic to the CRO and CMO fields.
Safety Polo Shirts,Safety Green Shirts,Safety Shirt,Long Sleeve Construction Work Shirts
Ningbo Staneex Imp. & Exp. Co., Ltd. , https://www.staneex.com